Sedentary behaviour
Conditions
Interventions
Participants will have four measurement days, in which they will be asked to
sit for three hours uninterruptedly during two of these days. The other two
days they will be asked to stay seated for th
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - 70-90 years of age - Mentally able to give informed consent - Adequate visual and auditory acuity to complete neuropsychological testing - Scores on the MoCA of *24 - Able to sit for three hours uninterruptedly (no urinary urgency problems)
Exclusion criteria
Exclusion criteria: - Persons who are not physically able to perform light-intensity physical activity such as standing and walking. - Diagnosis of AD, any other type of dementia or MCI - History of familial early-onset dementia; first or second degree family member diagnosed with dementia aged *55 years of age - Enrolment in any investigational drug study - Diagnosis of or drug use for any major psychiatric disorder (a clinical diagnosis of major depressive disorder, bipolar or schizophrenia) e.g. Anti-depressants, anti-psychotics, lithium - Drug use that affects alertness from the evening before the measurement, till the end of the measurement day, e.g. Psycho pharmacy e.g. benzodiazepines (oxazepam, temazepam, zolpidem), over-the-counter medication (melatonine, valeriane) - Past history or MRI evidence of brain damage, including significant trauma, stroke, hydrocephalus, mental retardation, or serious neurological disorder - Vigorously active for more than 3 hours per week (based on SQUASH questionnaire)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main parameter of this study is the difference between the conditions between the change in cognitive measures, as measured by the TAP test before and after the three hour periods. Alertness, working memory, and flexibility will be measured. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cerebrovascular autoregulation will serve as an intermediate outcome. Changes in cerebral autoregulation and cerebrovascular reactivity will be measured before and after each of the 3 hour conditions as well. | — |
Countries
Netherlands
Outcome results
None listed